RecruitingPhase 1NCT06034002

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Sponsor

Incyte Corporation

Enrollment

290 participants

Start Date

Dec 4, 2023

Study Type

INTERVENTIONAL

Conditions

Myeloproliferative Neoplasms

Summary

This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCA033989 and a drug called Ruxolitinib for people with myeloproliferative neoplasms. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA033989

INCA033989 will be administered at protocol defined dose.

DRUGRuxolitinib

Rux will be administered according to Prescribing Information/SmPC.

Locations(13)

City of Hope Medical Center

Duarte, California, United States

Stanford Cancer Institute

Palo Alto, California, United States

University of Miami Health System

Miami, Florida, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Washington University School of Medicine

St Louis, Missouri, United States

Icahn School of Medicine At Mount Sinai

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Md Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06034002

Related Trials

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT0700811826 locations

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT0744169454 locations

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT033149741 location

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT0631359330 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0593635929 locations